Roland T. Skeel

TL;DR: The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group and increased with increasing number of anatomic sites involved with metastases, but within categories of Anatomic involvement, weight loss was associated with decreased median survival.

TL;DR: Questions are raised regarding the perceived generalizability of trial findings, the role of end points other than survival for clinical trials, the consequences of physician overestimation of patient accrual, and the impact of randomized trials on the behavior of clinicians.

TL;DR: A consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide is found.

TL;DR: A consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide is found.

TL;DR: Satisfactory palliation was observed in patients with pancreas cancer treated with 125I interstitial implant followed by PhD external beam photon therapy and 5‐FU, and patient survival did not seem superior to that of patients treated with PhD externalbeam therapy ± chemotherapy, a less morbid procedure.